Streamlining R&D Tax Claims for Clinical Trials in Australia
Research and Development Intellect Labs Research and Development Intellect Labs

Streamlining R&D Tax Claims for Clinical Trials in Australia

Clinical trials have long been viewed favourably under the R&D Tax Incentive Program. To recognise this, the program offers an efficient registration process for trials registered with the Therapeutic Goods Administration, reducing the administrative burden for biotech companies. This streamlined approach, along with support through Advance Overseas Findings (AOF), empowers Australian biotech firms to innovate and lead on the global stage.

Read More
How to Successfully Navigate the Overseas Finding Process for R&D Tax Incentives
Research and Development Intellect Labs Research and Development Intellect Labs

How to Successfully Navigate the Overseas Finding Process for R&D Tax Incentives

The Overseas Finding process is a crucial component of the Research & Development Tax Incentive (RDTI) in Australia, enabling companies to access a tax benefit for overseas activities that relate to an Australian R&D program. This guide explores the Overseas Finding process, the key conditions for eligibility, and recent ATO concerns as outlined in taxpayer alerts. We also highlight a successful case study with a cyber security innovator, Internet 2.0, to illustrate effective strategies for securing an Overseas Finding.

Read More
R&D Tax Incentives and the SME Turnover Dilemma
Research and Development Intellect Labs Research and Development Intellect Labs

R&D Tax Incentives and the SME Turnover Dilemma

The R&D Tax Incentive remains Australia’s primary program for supporting businesses undertaking R&D activities with an estimated $3.2 billion annual investment. The program uses a $20 million annual turnover threshold to determine a company’s R&D tax rebate, a threshold that has been unchanged since 2011. In our view, it is time to review this arbitrary line in the sand and ensure the R&DTI aligns with other SME policies so that highly innovative medium sized businesses are incentivised to continue their R&D investment as they grow.

Read More